{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:17:01Z","timestamp":1787015821274,"version":"build-2736575974"},"reference-count":34,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A simplified cascade\u2010of\u2010care may improve screening and treatment uptake among incarcerated individuals. We assessed the cost\u2010effectiveness of traditional and simplified screening and treatment in a London remand prison.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using empirical data from Her Majesty's Prison (HMP) Wormwood Scrubs, London, we designed a decision tree and Markov transition state model using national average data for HCV screening and treatment for the base\u2010case scenario. This compared two alternative strategies; (a) general prison population screening and treatment and (b) prioritising screening and treatment among people who inject drugs (PWID) combined with general prison population screening and treatment. Strategies varied the rates of screening (47%\u201090%), linkage\u2010to\u2010care (60%\u201086%) and treatment (21%\u201085%). Cost, utility and disease transition rates were obtained from existing literature. Outcome measures were as follows: screening, treatment and disease\u2010related costs per admitted individual, quality\u2010adjusted life years (QALYs). Incremental cost\u2010effectiveness ratios (ICERs) were calculated for each intervention. All costs and utilities were discounted at a rate of 3.5% per annum. Both univariate and probabilistic sensitivity analyses have been conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In our cohort of 5239 incarcerated individuals with an estimated chronic HCV prevalence of 2.6%, all strategy ICER values (\u00a33565\u201010\u00a0300) fell below the national willingness to pay threshold (\u00a330\u00a0000). Increased successful treatment (7%\u201054%) was observed by an optimising cascade\u2010of\u2010care. A robust sensitivity analysis identified treatment cost of, QALY for mild liver disease and probability of completing treatment as important factors that impact the ICER value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our remand setting, optimising adherence to the cascade\u2010of\u2010care is cost\u2010effective. Where universal screening is not practical, a stratified approach focused on intensive screening and treatment of PWID also results in increased treatment uptake and is highly cost\u2010effective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.14628","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T15:47:02Z","timestamp":1596556022000},"page":"2950-2960","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost\u2010effectiveness of strategies to improve HCV screening, linkage\u2010to\u2010care and treatment in remand prison settings in England"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3713-0277","authenticated-orcid":false,"given":"Zameer","family":"Mohamed","sequence":"first","affiliation":[{"name":"Department of Hepatology Imperial College London St Mary's Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Scott","sequence":"additional","affiliation":[{"name":"Disease Elimination Program Burnet Institute Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyaa","family":"Al\u2010Kurdi","sequence":"additional","affiliation":[{"name":"Care UK HMP Wormwood Scrubs London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowlan","family":"Selvapatt","sequence":"additional","affiliation":[{"name":"Department of Hepatology Imperial College London St Mary's Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Thursz","sequence":"additional","affiliation":[{"name":"Department of Hepatology Imperial College London St Mary's Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9011-2991","authenticated-orcid":false,"given":"Maud","family":"Lemoine","sequence":"additional","affiliation":[{"name":"Department of Hepatology Imperial College London St Mary's Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Hepatology Imperial College London St Mary's Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shevanthi","family":"Nayagam","sequence":"additional","affiliation":[{"name":"Department of Hepatology Imperial College London St Mary's Hospital London UK"},{"name":"Department of Infectious Disease Epidemiology School of Public Health Imperial College London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"World Health Organisation.Global health sector strategy on viral hepatitis 2016\u20132021. 2016. [10\/07\/2019];https:\/\/www.who.int\/hepatitis\/strategy2016\u20102021\/ghss\u2010hep\/en\/"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30325-5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30085-8"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-14-26"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30466-4"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30676-X"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.02.008"},{"key":"e_1_2_9_9_1","unstructured":"World Health Organisation.Reaching people who inject drugs and people in prisons \u2013 a must for hepatitis C elimination.2019. [10\/07\/2019];https:\/\/www.who.int\/hepatitis\/news\u2010events\/pwid\u2010prison\u2010hcv\u2010access\u2010story\/en\/"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13783"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003153"},{"issue":"6","key":"e_1_2_9_12_1","first-page":"1796","article-title":"Is increased hepatitis C virus case\u2010finding combined with current or 8\u2010week to 12\u2010week direct\u2010acting antiviral therapy cost\u2010effective in UK prisons?","volume":"63","author":"Martin NK","year":"2016","journal-title":"A prevention benefit analysis. Hepatology"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz088"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz383"},{"key":"e_1_2_9_15_1","unstructured":"Public Health England.Hepatitis C in England 2019; working to eliminate hepatitis C as a major public health threat.2019. [14\/08\/2019];https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/798270\/HCV_in\u2010England_2019.pdf"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.102608"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.07.004"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/cku252"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000199046"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta11110"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta10210"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9301300409"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X08315241"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b185"},{"key":"e_1_2_9_26_1","unstructured":"Public Health England.National engagement event for blood\u2010 borne virus (BBV) opt\u2010out testing in prisons in England 2017.2017.https:\/\/www.gov.uk\/government\/publications\/blood\u2010borne\u2010virus\u2010opt\u2010out\u2010testing\u2010in\u2010prisons\u2010summary\u2010report\u20102017"},{"key":"e_1_2_9_27_1","unstructured":"Public Health England.Improving testing rates for blood\u2010borne viruses in prisons and other secure settings.2014.https:\/\/www.gov.uk\/government\/publications\/improving\u2010testing\u2010rates\u2010for\u2010blood\u2010borne\u2010viruses\u2010in\u2010prisons\u2010and\u2010other\u2010secure\u2010settings"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13071"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0617"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.08.023"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.08.013"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29811"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i21.2323"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13779"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta15170"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.14628","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14628","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.14628","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T21:56:59Z","timestamp":1693864619000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.14628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/liv.14628"],"URL":"https:\/\/doi.org\/10.1111\/liv.14628","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"2020-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}